Ebola virus circulation in a non-epidemic Guinean rural area: a mixed-method approach to assessing endemicity

Castro Gbêmêmali Hounmenou,Fréderic Le Marcis,Djiba Kaba,Maladho Diaby,Abdoul-Karim Soumah,Haby Diallo,Guillaume Thaurignac,Saidouba Cherif Camara,Ahidjo Ayouba,Martine Peeters,Alpha-Kabinet Keita,Eric Delaporte,Abdoulaye Touré
DOI: https://doi.org/10.1016/j.ijid.2024.107129
IF: 12.073
2024-06-22
International Journal of Infectious Diseases
Abstract:Objectives This study aimed to investigate the prevalence of orthoebolavirus antibodies in Madina Oula, a non-epidemic rural area in Guinea, in 2022. Methods A cross-sectional study conducted from March 14 to April 3, 2022, involved recording household and socio-demographic characteristics, lifestyle data, and collecting dried blood spots (DBS) from 878 individuals in 235 households. DBS were tested using multiplex serology to detect antibodies to different orthoebolaviruses : Ebola (EBOV), Bundibugyo (BDBV), Sudan (SUDV), Reston (RESTV) and Bombali (BOMV). Seroprevalence was estimated with a 95% confidence interval (CI) and Z-test was performed to compare seropositivity between in children under 15 and those over 15 Household and participant characteristics were analyzed using descriptive statistic, and socio-historical conditions were discussed. Results Serological analysis conducted in 2022 on 878 participants revealed varying reactivity to orthoebolavirus antigens, notably with GP antigens, particularly glycoprotein SUDV (16%). Twenty-one samples exhibited reactivity with at least two antigens, with a median age of 27 years (interquartile range = 10.00 - 35.00) ranging from 2 to 80 years. There is no significant difference between seropositivity in children under 15 (2.86%) and those over 15 (2.14%). Antibody presence varied per village, with the highest prevalence observed in Ouassou and Dar-es-Salam. Conclusion Serological data in a region unaffected by recent Ebola outbreaks indicate possible orthoebolavirus endemicity, emphasizing the need for preparedness against known or novel orthoebolaviruses with potential cross-reactivity.
infectious diseases
What problem does this paper attempt to address?